Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
29 December 2015
Oryzon Genomics Receives 1.3M USD Public Aids to Advance Development of its Epigenetic Inhibitors
16 December 2015
ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease
10 December 2015
Oryzon Genomics Announces Listing on Madrid Stock Exchange
30 November 2015
ORYZON to Present at the Neuroscience R&D Technologies Conference
10 November 2015
Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001
4 November 2015
ORYZON Announces the Appointment of Mr. Antonio Fornieles, Ms. Isabel Aguilera and Mr. Ramon Adell as Independent Directors
27 October 2015
ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs
16 September 2015
ORYZON shareholders approve listing to the Spanish Continuous Market
7 September 2015
ORYZON achieves milestone in the clinical development of ORY-1001
31 August 2015
ORYZON to Present at the 13th Annual Discovery on target: Targeting Histone Methyltransferases and Demethylases meeting in BOSTON
Pages
1
2
3
next ›
last »